Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03940196 · ClinicalTrials.gov registry record · Phase 3
Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)
A Phase 3 study of Ovarian Cancer, sponsored by NovoCure.
- Completed
- Registry status
- Phase 3
- Development phase
- 540
- Enrollment target
- 20
- Study locations
NCT03940196: Completed Phase 3 study of Ovarian Cancer, sponsored by NovoCure.
NCT03940196 is a Phase 3 study of Ovarian Cancer that has completed, run by NovoCure. The registered enrollment target is 540 participants, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03940196, a Phase 3 study of Ovarian Cancer, has completed, sponsored by NovoCure.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 540 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer . The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
Conditions Studied
Interventions
- DRUG Paclitaxel
- DEVICE NovoTTF-100L(O)
Study Locations (20)
Colorado
- Rocky Mountain Cancer Centers - Aurora
- University of Colorado Denver - Aurora
- Rocky Mountain Cancer Centers - Boulder
- Rocky Mountain Cancer Centers - Colorado Springs
- Rocky Mountain Cancer Centers - Denver
- Rocky Mountain Cancer Centers - Denver
- Rocky Mountain Cancer Centers - Lakewood
- Rocky Mountain Cancer Centers - Littleton
- Rocky Mountain Cancer Centers - Lone Tree
- Rocky Mountain Cancer Centers - Longmont
- Rocky Mountain Cancer Centers - Parker
- Rocky Mountain Cancer Centers - Pueblo
- Rocky Mountain Cancer Centers - Thornton
California
- University of California - La Jolla
- Hoag Memorial Hospital Presbyterian - Newport Beach
- California Pacific Medical Center- Pacific Campus - San Francisco
- Olive View - UCLA Medical Center - Sylmar
Arizona
- Arizona Oncology- Biltmore Cancer Center - Phoenix
- Arizona Oncology - Tucson
Florida
- Broward Health Medical Center - Fort Lauderdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 540 participants |
| Start Date | 2019-03-22 |
| Est. Completion | 2023-05-18 |
| Phase | Phase 3 |
What the finished NCT03940196 record still lists
NCT03940196 is an interventional study that assigns participants to a tested intervention. The registered 540 participants enrollment target is mid-sized for trials with a published cap, below the 727-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (26% lower).
The record links to 1 condition, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.
NCT03940196 names 20 study sites across 4 states, led by Colorado, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03940196 about?
NCT03940196 is a clinical study titled "Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)". The study is a prospective, randomized controlled phase III trial aimed to test the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer . The device is an experimental, portable, battery operated device for chronic ...
What is the current status of trial NCT03940196?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 540 participants. The study started on 2019-03-22. Estimated completion is 2023-05-18.
What conditions does trial NCT03940196 study?
This clinical trial studies the following conditions: Ovarian Cancer.
What interventions are being tested in trial NCT03940196?
The interventions under investigation include: Paclitaxel (DRUG), NovoTTF-100L(O) (DEVICE).
Who is sponsoring clinical trial NCT03940196?
This trial is sponsored by NovoCure, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03940196 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03940196's enrollment target sits among peer trials
540 43rd of 322 higher than 280 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04557462 · 540 participants · Phase 3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
- NCT04956640 · 540 participants · Phase 1
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
- NCT05429892 · 540 participants · NA
FRESH Delivers: An Innovative Approach to Reducing Tobacco Use Among Rural Smokers
- NCT05549297 · 540 participants · Phase 3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI